Basic information Safety Supplier Related

Satraplatin

Basic information Safety Supplier Related

Satraplatin Basic information

Product Name:
Satraplatin
Synonyms:
  • bis(acetato-o)amminedichloro(cyclohexanamine)-pt
  • platinum (lv) cis-dichloro-trans-bis(acetato-o)ammine(cyclohexanamine)
  • SATRAPLATIN
  • JM 216
  • Bis-acetatoamminedichlorocyclohexylamine platinum(iv)
  • C081294
  • Platinum, bis(acetato-o)amminedichloro(cyclohexanamine)-, (oc-6-43)-
  • Satraplatin(JM216)
CAS:
129580-63-8
MF:
C10H22Cl2N2O4Pt
MW:
500.28
Product Categories:
  • Anticancer
Mol File:
129580-63-8.mol
More
Less

Safety Information

Toxicity
LD50 in mice (mg/kg): 30 i.p.; 330 orally (Kelland)
More
Less

Satraplatin Usage And Synthesis

Uses

Antineoplastic.

Definition

ChEBI: A platinum coordination entity that consists of a central platunum atom bound to chloro (x2), acetate (x2), amino, and cyclohexylamino groups. Used for treatment of advanced prostate cancer.

Pharmaceutical Applications

Satraplatin (JM216, cis,trans,cis-[PtCl2(OAc)2(NH3)(C6H5NH2)]) is a Pt(IV) or Pt4+ complex, which is active by oral administration, as it is more hydrophobic than cisplatin. This form of administration is very attractive because of the convenience and freedom it provides to the patient. Satraplatin also has a milder toxicity profile and is shows no cross-resistance with cisplatin. Satraplatin in combination with prednisone has completed phase III clinical trials against hormone-refractory prostate cancer. The results were very encouraging, but the overall survival rate did not improve significantly enough. As a result, the fast-track approval of the FDA was not granted.
Structurally, satraplatin consists of a Pt(IV) centre, which is coordinated by six ligands forming a close to octahedral geometry. In general, octahedral Pt(IV) complexes (low-spin d6) are much more kinetically inert than square planar Pt(II) complexes.

Clinical Use

This newest organometallic agent currently is in clinical trials as a second-line agent for the treatment of hormone-refractory prostate cancer . There is hope that it also will find value in ovarian cancer and small cell lung cancer.

Side effects

As with other organoplatinum complexes, the diaquo form is active. At this early stage, the toxicity profile appears to be mild, with dose-related myelosuppression, particularly neutropenia and thrombocytopenia, being the major use-limiting side effect.

Metabolism

Unlike the square-planar Pt(II) complexes currently on the market, it is active by the oral route. It is metabolized quickly in whole blood, producing up to six metabolites. The major metabolite is the desacetoxy analogue.

SatraplatinSupplier

3B Pharmachem (Wuhan) International Co.,Ltd.
Tel
821-50328103-801 18930552037
Email
3bsc@sina.com
Chembest Research Laboratories Limited
Tel
021-20908456
Email
sales@BioChemBest.com
LGM Pharma
Tel
1-(800)-881-8210
Email
inquiries@lgmpharma.com
Wuhan Fortuna Chemical Co., Ltd
Tel
027-59207852 13308628970
Email
buy@fortunachem.com
Beijing HuaMeiHuLiBiological Chemical
Tel
010-56205725
Email
waley188@sohu.com